We gather today to remember the old treatment plan for advanced head-and-neck adenoid cystic carcinoma: watch carefully, try something reasonable, cross several fingers, and hope the tumor forgets it has places to be.
Adenoid cystic carcinoma, or ACC, is rare, slow-growing, and deeply annoying in the way only cancer biology can be. It often starts in salivary glands or nearby head-and-neck tissues, and it has a particular fondness for creeping along nerves. In other words, ACC is not always loud, but it is the kind of houseguest who quietly opens every drawer.
That is why a new phase II study of liposomal doxorubicin plus nab-paclitaxel, with chemoradiotherapy for selected patients, is worth a close look. Not a victory parade. Not “cancel all future trials.” But definitely a “wait, did that tumor just shrink?” moment.
The Tiny Drug Taxis Have Arrived
The study tested two familiar chemotherapy drugs wearing upgraded delivery outfits. Doxorubicin came packaged in liposomes, tiny fat bubbles that help change where and how the drug travels. Paclitaxel came as nab-paclitaxel, meaning it is bound to albumin, a normal blood protein. Basically, instead of throwing chemotherapy into the bloodstream like glitter at a wedding you regret attending, these formulations try to make delivery a bit more organized.
Thirty-one patients with unresectable locally advanced or recurrent/metastatic head-and-neck ACC received liposomal doxorubicin plus nab-paclitaxel on days 1 and 8 of 21-day cycles. After three cycles, patients who could receive radiation moved on to concurrent chemoradiotherapy, while others continued chemotherapy alone [1].
The headline result: the objective response rate was 90.3%. That included complete responses in 48.4% and partial responses in 41.9%. Median progression-free survival was 25.7 months, and median overall survival had not been reached at a median follow-up of 15.7 months [1].
For ACC, those numbers are not subtle. They are the oncology equivalent of someone entering a quiet library by crashing through the window.
Why That Number Made People Sit Up Straighter
ACC has been stubbornly hard to treat once surgery and radiation are no longer enough. Reviews describe a disease with late recurrences, distant metastases, and no tidy one-size-fits-all systemic therapy [2,3]. Immunotherapy, which has been a superhero in some cancers, often walks into ACC and finds a room with no good lighting, no snacks, and very few immune targets. Trials of checkpoint inhibitors in salivary gland cancers have shown limited activity in ACC, with occasional exceptions [4].
Targeted therapies have done better at disease control than dramatic shrinkage. A 2024 systematic review of VEGFR inhibitors in recurrent or metastatic ACC found a pooled objective response rate of only 6%, though stable disease was common at 82% [5]. Translation: many tumors stopped sprinting, but few actually packed a suitcase and left.
So a 90.3% response rate in this new study stands out. It suggests that old-school chemotherapy, when delivered with newer packaging and timed thoughtfully, might still have moves. Like discovering your dad can somehow beat everyone at Dance Dance Revolution.
The Fine Print, Wearing Sensible Shoes
Now the brakes. This was a single-arm study. Everyone got the treatment; there was no randomized comparison group. The sample size was small, because ACC is rare and trials in rare cancers are hard to run. Also, the patients who went on to chemoradiotherapy were not identical to those who did not; they tended to be less heavily pretreated. That makes the radiation subgroup look promising, but not definitive.
Safety looked manageable, though not invisible. Grade 3 treatment-related adverse events occurred in 25.8% of patients, including hand-foot syndrome, mouth inflammation, and low white blood cells. No grade 4 or higher treatment-related events and no treatment-related deaths were reported [1]. Still, “manageable” in oncology does not mean “a spa weekend.” It means clinicians had tools to adjust doses and support patients when toxicity showed up with a clipboard.
What This Could Mean If It Holds Up
If larger studies reproduce these results, this approach could give clinicians a more active option for people with advanced head-and-neck ACC, especially patients who need real tumor shrinkage rather than just temporary disease parking. Shrinking tumors can matter in very practical ways: less pain, less pressure on nearby structures, easier breathing or swallowing, and possibly a clearer path to radiation for selected patients.
It also nudges the field toward a useful idea: delivery matters. Cancer drugs are not just what you give, but how they travel, where they concentrate, and whether the tumor gets a bigger dose than the rest of the body. Basically, pharmacology is logistics with more nausea.
The next step is obvious but difficult: larger, preferably randomized studies, longer follow-up, independent response review, quality-of-life data, and biomarkers that tell us who is most likely to benefit. Because the only thing worse than a rare cancer is a rare cancer with vague instructions.
For now, this study does not rewrite the rulebook. It scribbles a bold note in the margin: maybe the old chemotherapy tools, packed into smarter little carriers, deserve another serious look.
References
-
Zhang X, Wei J, Chen N, et al. Liposomal doxorubicin plus nab-paclitaxel with/without chemoradiotherapy in head and neck adenoid cystic carcinoma: single-arm phase II study. Signal Transduction and Targeted Therapy. 2026;11:230. doi:10.1038/s41392-026-02725-1
-
Zupancic M, Näsman A, Friesland S, Dalianis T. Adenoid cystic carcinoma, clinical presentation, current treatment and approaches toward novel therapies. Anticancer Research. 2024;44:1325-1334. doi:10.21873/anticanres.16929
-
Nightingale J, Lum B, Ladwa R, Simpson F, Panizza B. Adenoid cystic carcinoma: a review of clinical features, treatment targets and advances in improving the immune response to monoclonal antibody therapy. Biochimica et Biophysica Acta Reviews on Cancer. 2021;1875:188523. doi:10.1016/j.bbcan.2021.188523
-
Vos JL, et al. Nivolumab plus ipilimumab in advanced salivary gland cancer: a phase 2 trial. Nature Medicine. 2023;29:3077-3089. doi:10.1038/s41591-023-02518-x
-
Hoff CO, Manzi J, Ferrarotto R. Vascular endothelial growth factor receptor inhibitors for recurrent or metastatic adenoid cystic carcinoma: a systematic review and meta-analysis. JAMA Otolaryngology Head & Neck Surgery. 2024;150:650-660. doi:10.1001/jamaoto.2024.1177 PMCID: PMC11140580
Disclaimer: The image accompanying this article is for illustrative purposes only and does not depict actual experimental results, data, or biological mechanisms.